Time-dependent pharmacokinetic changes and renal SGLT2 expression alterations of dapagliflozin under high-altitude hypoxia in diabetic rats
5 affiliations
- 1Department of Pharmacy, The 940th Hospital of Joint Logistics Support Force of Chinese People’s Liberation Army
- 2School of Pharmacy, Ningxia Medical University
- 3Department of Pharmacy, The Second Hospital & Clinical Medical School, Lanzhou University
- 4Yushu Tibetan Autonomous Prefecture People’s Hospital
- 5Ningxia Hui Autonomous Region Fifth People’s Hospital
Abstract
Objective: This study investigated the time-dependent effects of high-altitude hypoxia on the pharmacokinetics (PK), renal sodium-glucose cotransporter 2 (SGLT2) expression, and glycemic response to dapagliflozin in type 2 diabetes mellitus (T2DM) rats.
Methods: T2DM was induced in male Wistar rats via high-fat diet and low-dose streptozotocin. In the acute study, rats received a single oral dose of dapagliflozin (1 mg/kg) after a 3-day exposure to normoxia or simulated 6000 m hypoxia. In the chronic study, rats received daily dapagliflozin (1 mg/kg) during a 14-day period under normoxia or chronic hypoxia. Plasma dapagliflozin concentrations were determined by UPLC-MS/MS. Fasting blood glucose was monitored serially, and renal cortical SGLT2 protein levels were quantified by ELISA at study endpoint. Individual exposure–response relationships were assessed by Spearman correlation.
Results: Acute hypoxia caused a dramatic PK perturbation: AUC 0-t and C max increased by 6.58-fold and 5.06-fold, respectively, compared with acute normoxia (all p < 0.01). Chronic hypoxia produced a significant but attenuated effect: AUC 0-t and C max increased by 2.11-fold and 1.69-fold, respectively (all p < 0.01), representing an approximately 70% reduction in the magnitude of PK change under chronic versus acute exposure. Chronic hypoxia was also associated with significantly attenuated early glycemic reduction at days 4 and 7 ( p < 0.01), though fasting blood glucose levels converged by day 14. Although these observations were temporally associated, a direct causal link is not supported, as SGLT2 was measured only at day 14 whereas glycemic differences emerged earlier (days 4–7). Pooled analysis showed no significant correlation between dapagliflozin exposure and day-14 fasting blood glucose, whereas group-stratified analysis revealed a significant negative correlation between AUC 0-t and day-14 fasting blood glucose in normoxic rats only.
Conclusion: Dapagliflozin pharmacokinetics undergo time-dependent adaptation under high-altitude hypoxia. Exposure–response analysis suggested a hypoxia-induced dissociation between dapagliflozin exposure and glycemic response. These findings underscore the need for dedicated clinical PK–PD monitoring in high-altitude populations and provide a descriptive framework for future mechanistic and translational investigations.
Related
- Exposure-duration-associated auditory dysfunction and cochlear presynaptic ribbon alterations during simulated high-altitude hypobaric hypoxia in mice
- Taurine ameliorates negative energy balance-induced gene expression alterations in buffalo granulosa cells
- Metagenomic insights into dose-dependent alterations in the tobacco rhizosphere microbiome by pyrroloquinoline quinone
- Juvenile behavioral alterations and sex-dependent deficits in hippocampal neurogenesis following early-life stress in rats
- Depth-Dependent Alterations in Cerebral Blood and Tissue Oxygenation Associated with Tau in Alzheimer's Disease Models
BibTeX
@article{tong2026timedependent,
title = {{Time-dependent pharmacokinetic changes and renal SGLT2 expression alterations of dapagliflozin under high-altitude hypoxia in diabetic rats}},
author = {Yinlian Tong and Chang Wang and Yuemei Sun and Xiaojing Zhang and Huijun Fang and Yuan Xie and Yan Xiao and Shengping Ma and Wenbin Li and Rong Wang},
journal = {Frontiers in Pharmacology},
year = {2026},
month = oct,
doi = {10.3389/fphar.2026.1931102},
url = {https://www.frontiersin.org/articles/10.3389/fphar.2026.1931102/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Time-dependent pharmacokinetic changes and renal SGLT2 expression alterations of dapagliflozin under high-altitude hypoxia in diabetic rats
AU - Yinlian Tong
AU - Chang Wang
AU - Yuemei Sun
AU - Xiaojing Zhang
AU - Huijun Fang
AU - Yuan Xie
AU - Yan Xiao
AU - Shengping Ma
AU - Wenbin Li
AU - Rong Wang
PY - 2026
DA - 2026/10/26
JO - Frontiers in Pharmacology
DO - 10.3389/fphar.2026.1931102
UR - https://www.frontiersin.org/articles/10.3389/fphar.2026.1931102/full
AB - Objective: This study investigated the time-dependent effects of high-altitude hypoxia on the pharmacokinetics (PK), renal sodium-glucose cotransporter 2 (SGLT2) expression, and glycemic response to dapagliflozin in type 2 diabetes mellitus (T2DM) rats. Methods: T2DM was induced in male Wistar rats via high-fat diet and low-dose streptozotocin. In the acute study, rats received a single oral dose of dapagliflozin (1 mg/kg) after a 3-day exposure to normoxia or simulated 6000 m hypoxia. In the chronic study, rats received daily dapagliflozin (1 mg/kg) during a 14-day period under normoxia or chronic hypoxia. Plasma dapagliflozin concentrations were determined by UPLC-MS/MS. Fasting blood glucose was monitored serially, and renal cortical SGLT2 protein levels were quantified by ELISA at study endpoint. Individual exposure–response relationships were assessed by Spearman correlation. Results: Acute hypoxia caused a dramatic PK perturbation: AUC 0-t and C max increased by 6.58-fold and 5.06-fold, respectively, compared with acute normoxia (all p < 0.01). Chronic hypoxia produced a significant but attenuated effect: AUC 0-t and C max increased by 2.11-fold and 1.69-fold, respectively (all p < 0.01), representing an approximately 70% reduction in the magnitude of PK change under chronic versus acute exposure. Chronic hypoxia was also associated with significantly attenuated early glycemic reduction at days 4 and 7 ( p < 0.01), though fasting blood glucose levels converged by day 14. Although these observations were temporally associated, a direct causal link is not supported, as SGLT2 was measured only at day 14 whereas glycemic differences emerged earlier (days 4–7). Pooled analysis showed no significant correlation between dapagliflozin exposure and day-14 fasting blood glucose, whereas group-stratified analysis revealed a significant negative correlation between AUC 0-t and day-14 fasting blood glucose in normoxic rats only. Conclusion: Dapagliflozin pharmacokinetics undergo time-dependent adaptation under high-altitude hypoxia. Exposure–response analysis suggested a hypoxia-induced dissociation between dapagliflozin exposure and glycemic response. These findings underscore the need for dedicated clinical PK–PD monitoring in high-altitude populations and provide a descriptive framework for future mechanistic and translational investigations.
SN - 1663-9812
ER -